Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
AssigneeLorus Therapeutics Inc.
InventorsJim A. Wright, Aiping H. Young
Life of this patent
Estimating the term…
Abstract
Compounds and methods for modulating cell proliferation, preferably inhibiting the proliferation of tumor cells are described. Compounds that may be used to modulate cell proliferation include antisense oligonucleotides complementary to regions of the mammalian ribonucleotide reductase genes.
Claims73
A method of increasing sensitivity of leukemia cells to a chemotherapeutic drug in a mammal, said method comprising contacting the leukemia cells with an effective amount of an antisense oligonucleotide of between 12 and 100 nucleotides in length comprising a sequence as set forth in any one of SEQ ID NOs:
- 3 to 102, wherein said sequence is complementary to a mRNA sequence of a mammalian ribonucleotide reductase protein component R2.
A method for inhibiting the proliferation of leukemia cells in a mammal, said method comprising contacting leukemia cells with an effective amount of an antisense oligonucleotide of between 12 and 100 nucleotides in length comprising a sequence as set forth in any one of SEQ ID NOs:
- 3 to 102, wherein said sequence is complementary to a mRNA sequence of a mammalian ribonucteotide reductase protein component R2.
A method of treating leukemia in a mammal comprising administering to said mammal an effective amount of an antisense oligonucleotide of between 12 and 100 nucleotides in length comprising a sequence as set forth in any one of SEQ ID NOs:
- 3 to 102, wherein said sequence is complementary to a mRNA sequence of a mammalian ribonucleotide reductase protein component R2.
A method of treating leukemia in a human comprising administering to said human an effective amount of an antisense oligonucleotide of between 12 and 100 nucleotides in length comprising at least 7 consecutive nucleotides from SEQ ID NO:
- 42.
A method for inhibiting the proliferation of leukemia cells in a mammal, said method comprising contacting leukemia cells with an effective amount of an antisense oligonucleotide of between 12 and 100 nucleotides in length comprising a sequence as set forth in any one of SEQ ID NOs:
- 3 to 102, wherein said sequence is complementary to a mRNA sequence of a mammalian ribonucleotide reductase protein component R2 in combination with one or more chemotherapeutic agents.
A method of treating leukemia in a mammal comprising administering to said mammal an effective amount of an antisense oligonucleotide of between 12 and 100 nucleotides in length comprising a sequence as set forth in any one of SEQ ID NOs:
- 3 to 102, wherein said sequence is complementary to a mRNA sequence of a mammalian ribonucleotide reductase protein component R2 in combination with one or more chemotherapeutic agents.
A method of treating leukemia in a human comprising administering to said human an effective amount of an antisense oligonucleotide of between 12 and 100 nucleotides in length comprising at least 7 consecutive nucleotides from SEQ ID NO:
- 42 in combination with one or more chemotherapeutic agents.
A method of treating a solid cancer in a mammal comprising administering to said mammal an effective amount of an antisense oligonucleotide of between 12 and 100 nucleotides in length comprising at least 7 consecutive nucleotides of a sequence as set forth in SEQ ID NO:
- 42, wherein said solid cancer is a bladder cancer, a colon cancer, a lung cancer, a breast cancer, a pancreatic cancer, a prostate cancer, a liver cancer, a cervical cancer or a melanoma.
A method of treating a proliferative disorder in a mammal comprising administering to said mammal an effective amount of an antisense oligonucleotide of between 12 and 100 nucleotides in length comprising at least 7 consecutive nucleotides of a sequence as set forth in SEQ ID NO:
- 42.
Dependencies are inferred from the claim text.